Interplay Between N 6-Methyladenosine (m6A) and Non-coding RNAs in Cell Development and Cancer - PubMed (original) (raw)
Review
Interplay Between N 6-Methyladenosine (m6A) and Non-coding RNAs in Cell Development and Cancer
Francesco Fazi et al. Front Cell Dev Biol. 2019.
Abstract
RNA chemical modifications in coding and non-coding RNAs have been known for decades. They are generally installed by specific enzymes and, in some cases, can be read and erased by other specific proteins. The impact of RNA chemical modifications on gene expression regulation and the reversible nature of some of these modifications led to the birth of the word epitranscriptomics, in analogy with the changes that occur on DNA and histones. Among more than 100 different modifications identified so far, most of the epitranscriptomics studies focused on the N 6-methyladenosine (m6A), which is the more abundant internal modification in protein coding RNAs. m6A can control several pathways of gene expression, including spicing, export, stability, and translation. In this review, we describe the interplay between m6A and non-coding RNAs, in particular microRNAs and lncRNAs, with examples of its role in gene expression regulation. Finally, we discuss its relevance in cell development and disease.
Keywords: ESC development; RNA modifications; cell reprogramming; epitranscriptomics; lncRNAs; m6A; microRNAs; non-coding RNAs.
Figures
FIGURE 1
Impact of epitranscriptomics on microRNAs biogenesis and function. (A) m6A stimulates microRNA processing by recruiting the Drosha cofactor DGCR8 by the m6A reader HNBRPA2B1 (Alarcón et al., 2015a, b) or, in the case of the miR-126a, by direct interaction with METTL14 (Ma et al., 2017). (B) During aging of peripheral blood mononuclear cells (PBMCs), AGO2 and, eventually, miRNA levels are decreased by higher m6A modification of AGO2 mRNA. This results in enhanced mRNA decay that is very likely mediated by the YTHDF2 reader (Min et al., 2018).
FIGURE 2
Examples of the interplay between non-coding RNAs and epitranscriptomics. (A) In glioblastoma stem-like cells (GSCs) the expression of FOXM1 is increased by the concomitant expression of the antisense transcript FOXM1-AS, which, in turn, promote m6A demethylation by recruiting ALKBH5 (Zhang et al., 2017). (B) m6A RNA methylation is positively regulated by microRNAs, which recruit METTL3 on specific mRNA and promotes reprogramming to pluripotency (Chen et al., 2015). (C) m6A modification decreases the IGFBP3 mRNA levels by inhibiting the binding of HuR and promoting the interaction with microRNAs. IGFBP3 protein positively regulates the stability of different developmental regulators. This mechanism ensures low level of IGFBP3 in mESCs (Wang Y. et al., 2014).
Similar articles
- The functions of N6-methyladenosine modification in lncRNAs.
He RZ, Jiang J, Luo DX. He RZ, et al. Genes Dis. 2020 Mar 19;7(4):598-605. doi: 10.1016/j.gendis.2020.03.005. eCollection 2020 Dec. Genes Dis. 2020. PMID: 33335959 Free PMC article. Review. - N6-Methyladenosine (m6A): A Promising New Molecular Target in Acute Myeloid Leukemia.
Ianniello Z, Paiardini A, Fatica A. Ianniello Z, et al. Front Oncol. 2019 Apr 9;9:251. doi: 10.3389/fonc.2019.00251. eCollection 2019. Front Oncol. 2019. PMID: 31024852 Free PMC article. Review. - Environmental exposures and RNA N6-Methyladenosine modified long Non-Coding RNAs.
Cayir A. Cayir A. Crit Rev Toxicol. 2020 Sep;50(8):641-649. doi: 10.1080/10408444.2020.1812511. Epub 2020 Sep 14. Crit Rev Toxicol. 2020. PMID: 32924714 Review. - Role of N6-Methyladenosine RNA Modification in Cardiovascular Disease.
Song D, Hou J, Wu J, Wang J. Song D, et al. Front Cardiovasc Med. 2021 May 7;8:659628. doi: 10.3389/fcvm.2021.659628. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34026872 Free PMC article. Review. - The Dark Side of the Epitranscriptome: Chemical Modifications in Long Non-Coding RNAs.
Jacob R, Zander S, Gutschner T. Jacob R, et al. Int J Mol Sci. 2017 Nov 10;18(11):2387. doi: 10.3390/ijms18112387. Int J Mol Sci. 2017. PMID: 29125541 Free PMC article. Review.
Cited by
- Overview of the interplay between m6A methylation modification and non-coding RNA and their impact on tumor cells.
Dou Z, Ma XT, Piao MN, Wang JP, Li JL. Dou Z, et al. Transl Cancer Res. 2024 Jun 30;13(6):3106-3125. doi: 10.21037/tcr-23-2401. Epub 2024 Jun 27. Transl Cancer Res. 2024. PMID: 38988908 Free PMC article. Review. - Regulation of N6-Methyladenosine in the Differentiation of Cancer Stem Cells and Their Fate.
Xu Y, Liu J, Chen WJ, Ye QQ, Chen WT, Li CL, Wu HT. Xu Y, et al. Front Cell Dev Biol. 2020 Sep 22;8:561703. doi: 10.3389/fcell.2020.561703. eCollection 2020. Front Cell Dev Biol. 2020. PMID: 33072746 Free PMC article. Review. - m6A-related lncRNAs are potential biomarkers for predicting prognoses and immune responses in patients with LUAD.
Xu F, Huang X, Li Y, Chen Y, Lin L. Xu F, et al. Mol Ther Nucleic Acids. 2021 Apr 9;24:780-791. doi: 10.1016/j.omtn.2021.04.003. eCollection 2021 Jun 4. Mol Ther Nucleic Acids. 2021. PMID: 33996259 Free PMC article. - A Prognostic Signature for Colon Adenocarcinoma Patients Based on m6A-Related lncRNAs.
Zhou SZ, Pan YL, Deng QC, Yin CJ, Zhou DJ, Liu ML, Zhou J, Wu XJ. Zhou SZ, et al. J Oncol. 2023 Feb 13;2023:7797710. doi: 10.1155/2023/7797710. eCollection 2023. J Oncol. 2023. PMID: 36814559 Free PMC article. - Comprehensive Analysis of Long Noncoding RNA Modified by m6A Methylation in Oxidative and Glycolytic Skeletal Muscles.
Wang S, Tan B, Xiao L, Zhao X, Zeng J, Hong L, Yang J, Cai G, Zheng E, Wu Z, Gu T. Wang S, et al. Int J Mol Sci. 2022 Apr 21;23(9):4600. doi: 10.3390/ijms23094600. Int J Mol Sci. 2022. PMID: 35562992 Free PMC article.
References
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources